Log in

OTCMKTS:PXRB - Pixarbio Stock Price, Forecast & News

0.00 (0.00 %)
(As of 02/27/2020 03:56 AM ET)
Today's Range
Now: $0.00
50-Day Range
MA: $0.01
52-Week Range
Now: $0.00
Volume25 shs
Average VolumeN/A
Market Capitalization$8,150.00
P/E RatioN/A
Dividend YieldN/A
PixarBio Corporation, a specialty pharmaceutical/biotechnology company, focuses on the pre-clinical and clinical development of neurological drug delivery systems for post-operative pain. The company researches and develops delivery systems for drugs, devices, or biologics to treat pain, epilepsy, epilepsy, Parkinson's disease, and spinal cord injury. Its principal product platform is NeuroRelease for the therapeutic release of non-opiate drugs for post-operative, acute, and chronic pain in pre-clinical models. The company is based in Medford, Massachusetts.

Industry, Sector and Symbol

Industry Membership sports & recreation clubs
Current SymbolOTCMKTS:PXRB



Sales & Book Value

Annual SalesN/A



Market Cap$8,150.00
Next Earnings DateN/A
OptionableNot Optionable

Receive PXRB News and Ratings via Email

Sign-up to receive the latest news and ratings for PXRB and its competitors with MarketBeat's FREE daily newsletter.

Pixarbio (OTCMKTS:PXRB) Frequently Asked Questions

What is Pixarbio's stock symbol?

Pixarbio trades on the OTCMKTS under the ticker symbol "PXRB."

Has Pixarbio been receiving favorable news coverage?

Media stories about PXRB stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pixarbio earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Pixarbio.

Who are some of Pixarbio's key competitors?

What other stocks do shareholders of Pixarbio own?

Who are Pixarbio's key executives?

Pixarbio's management team includes the folowing people:
  • Mr. Francis M. Reynolds, Co-Founder, Chairman, CEO, CFO, Chief Scientific Officer & Corp. Sec. (Age 56)
  • Dr. Jason Criscione, Co-Founder and Chief Technology Officer (Age 37)
  • Dr. Amer Khalil, Co-Founder, MD & Member of Scientific Advisory Board
  • Mr. Haining Dai, Co-Founder & Director of Preclinical Neuroscience
  • Ms. Xi Chen, Co-Founder & Director of Analytical Chemistry

How do I buy shares of Pixarbio?

Shares of PXRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pixarbio's stock price today?

One share of PXRB stock can currently be purchased for approximately $0.00.

How big of a company is Pixarbio?

Pixarbio has a market capitalization of $8,150.00. View Additional Information About Pixarbio.

What is Pixarbio's official website?

The official website for Pixarbio is http://www.buddhimatyoga.com/.

How can I contact Pixarbio?

Pixarbio's mailing address is 200 BOSTON AVE. STE. 1875, MEDFORD MA, 02155. The company can be reached via phone at 617-803-8838 or via email at [email protected]

MarketBeat Community Rating for Pixarbio (OTCMKTS PXRB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  59
MarketBeat's community ratings are surveys of what our community members think about Pixarbio and other stocks. Vote "Outperform" if you believe PXRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel